Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16849230 | 0.86 | CYP1A2 (0.38) | CYP1A2CYP2D6F10PRSS1PRSS2 | |
| SCHEMBL15726879 | 0.84 | TDP1 (0.36) | GBA1 | |
| SCHEMBL15723284 | 0.81 | CYP2D6 (0.37) | CYP1A2CYP2D6F10PRSS1PRSS2 | |
| SCHEMBL15723286 | 0.77 | HSP90AA1 (0.35) | CYP1A2CYP2D6BCHEACHEGRIA4 | |
| SCHEMBL16259542 | 0.75 | TRPV4 (0.36) | CYP1A2CYP2D6GRIA4 | |
| SCHEMBL15723288 | 0.73 | ALDH1A1 (0.46) | — | |
| SCHEMBL24869560 | 0.72 | GSTO1 (0.41) | — | |
| SCHEMBL16259658 | 0.71 | GRIA4 (0.40) | F10PRSS1PRSS2PRSS3GRIA4 | |
| SCHEMBL16259567 | 0.70 | CA1 (0.38) | F10PRSS1PRSS2PRSS3GRIA4 | |
| SCHEMBL15723299 | 0.70 | CNR1 (0.40) | GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301272-B2 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | PHENEX PHARMACEUTICALS AG (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | PHENEX PHARMACEUTICALS AG (DE) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175562-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] | RORA, RORB, RORC | CYP1A2 461/4885CYP2D6 1162/4885F10 4225/4885 |
| US-10301272-B2 | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] | RORA, RORB, RORC | CYP1A2 429/4885CYP2D6 1166/4885F10 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.